A detailed history of Chi Advisors LLC transactions in Ovid Therapeutics Inc. stock. As of the latest transaction made, Chi Advisors LLC holds 864,822 shares of OVID stock, worth $864,822. This represents 1.64% of its overall portfolio holdings.

Number of Shares
864,822
Previous 864,822 -0.0%
Holding current value
$864,822
Previous $2.84 Million 17.07%
% of portfolio
1.64%
Previous 1.07%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 12, 2022

BUY
$1.69 - $3.31 $20,168 - $39,501
11,934 Added 1.4%
864,822 $1.86 Million
Q1 2022

May 16, 2022

BUY
$2.65 - $3.49 $1.2 Million - $1.58 Million
452,888 Added 113.22%
852,888 $2.68 Million
Q4 2021

Feb 11, 2022

BUY
$3.13 - $3.73 $521,113 - $621,007
166,490 Added 71.3%
400,000 $1.28 Million
Q3 2021

Nov 15, 2021

BUY
$3.31 - $4.04 $49,650 - $60,600
15,000 Added 6.86%
233,510 $785,000
Q2 2021

Aug 11, 2021

SELL
$3.3 - $4.49 $95,700 - $130,210
-29,000 Reduced 11.72%
218,510 $854,000
Q1 2021

May 14, 2021

SELL
$2.42 - $4.47 $1.4 Million - $2.59 Million
-579,750 Reduced 70.08%
247,510 $995,000
Q4 2020

Feb 12, 2021

BUY
$2.28 - $6.84 $476,903 - $1.43 Million
209,168 Added 33.84%
827,260 $1.91 Million
Q3 2020

Nov 12, 2020

BUY
$5.39 - $8.24 $397,841 - $608,202
73,811 Added 13.56%
618,092 $3.55 Million
Q2 2020

Aug 12, 2020

SELL
$2.67 - $7.91 $758,632 - $2.25 Million
-284,132 Reduced 34.3%
544,281 $4.01 Million
Q1 2020

May 14, 2020

SELL
$2.03 - $4.35 $31,501 - $67,503
-15,518 Reduced 1.84%
828,413 $2.47 Million
Q4 2019

Feb 14, 2020

BUY
$2.08 - $5.06 $242,675 - $590,355
116,671 Added 16.04%
843,931 $3.5 Million
Q3 2019

Nov 12, 2019

BUY
$1.76 - $3.51 $1.28 Million - $2.55 Million
727,260 New
727,260 $2.36 Million

Others Institutions Holding OVID

About Ovid Therapeutics Inc.


  • Ticker OVID
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 70,419,400
  • Market Cap $70.4M
  • Description
  • Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment o...
More about OVID
Track This Portfolio

Track Chi Advisors LLC Portfolio

Follow Chi Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Chi Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Chi Advisors LLC with notifications on news.